Form 4: Tonix Pharmaceuticals Director James Hunter Jr. Granted Stock Options
Statement of Changes in Beneficial Ownership (Form 4)
Tonix Pharmaceuticals Holding Corp. Director James Randolph Hunter Jr. was granted 7,740 stock options with an exercise price of $34.54, vesting on the date of the Company's 2026 annual meeting of stockholders.
Summary
- James Randolph Hunter Jr., a Director of Tonix Pharmaceuticals Holding Corp. (TNXP), was granted 7,740 derivative securities in the form of stock options.
- The transaction date for this grant was June 12, 2025.
- The exercise price for these stock options is $34.54 per share.
- The options are set to vest on the date of the Company's 2026 annual meeting of stockholders.
- The expiration date for these stock options is June 12, 2035.
- The grant was made pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended.
- Following this transaction, James Randolph Hunter Jr. beneficially owns 7,740 derivative securities (stock options).
Sentiment
Score: 6
Explanation: The document reports a standard compensation event (stock option grant) to a director, which is generally viewed as neutral to slightly positive due to alignment of interests, but not a significant market-moving event.
Positives
- The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
Future Outlook
The granted stock options are set to vest on the date of the Company's 2026 annual meeting of stockholders, indicating a future milestone for the director's equity compensation.
Industry Context
The grant of stock options to directors is a common practice in the pharmaceutical and biotechnology industries, serving as a key component of executive and director compensation packages to attract and retain talent and align interests with long-term company performance.
Comparison to Industry Standards
- Stock option grants are a standard form of equity compensation for directors and executives across various industries, including pharmaceuticals, aligning their incentives with shareholder value creation.
- The structure of the grant, including a vesting period and a 10-year expiration, is typical for such compensation plans in publicly traded companies.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Plan Utilization | The stock option grant was made pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, indicating the ongoing use of an approved equity compensation framework. | 06/12/2025 | Reinforces the company's established compensation policies and practices for directors, aligning their long-term interests with the company's performance. |
| Power of Attorney Authorization | James Hunter Jr. has granted a Power of Attorney to Jessica Morris, Bradley Saenger, and Irina Ishak to execute and file SEC forms (including Forms 3, 4, and 5) on his behalf, ensuring compliance with reporting obligations. | 06/13/2025 | Streamlines the process for timely and accurate insider trading compliance filings, demonstrating adherence to regulatory requirements. |
Related Party Transactions
- The grant of stock options to James Randolph Hunter Jr., a Director of Tonix Pharmaceuticals Holding Corp., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.
Stakeholder Impact
- Shareholders: The grant of stock options to a director is intended to align the director's interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.
Next Steps
- The stock options will vest on the date of Tonix Pharmaceuticals Holding Corp.'s 2026 annual meeting of stockholders, at which point they can be exercised.
Key Dates
| Date | Description |
|---|---|
| 06/12/2025 | Date of earliest transaction (stock option grant). |
| 06/13/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
| 2026 Annual Meeting of Stockholders | Date when the granted stock options will vest. |
| 06/12/2035 | Expiration date of the granted stock options. |
Keywords
Tonix Pharmaceuticals, TNXP, Form 4, Stock Option Grant, Director Compensation, Insider Transaction, Equity Incentive Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.